Weight Gain in risperidone therapy: Investigation of peripheral hypothalamic neurohormone levels in psychotic patients

Journal of Clinical Psychopharmacology

Volumn 33, Issue 5, 2013, Pages 608-613

  Yanik, Tulin ^a   Kursungoz, Canan ^a   Sutcigil, Levent ^b   Ak, Mehmet ^c  

^a NIPPON MEDICAL SCHOOL GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Koutokukai   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERMEDIN; COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; LEPTIN; NEUROPEPTIDE Y; RISPERIDONE;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; HORMONE BLOOD LEVEL; HUMAN; HYPOTHALAMUS; MALE; MENTAL HOSPITAL; OUTPATIENT DEPARTMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHOSIS; SIDE EFFECT; SYMPATHETIC TONE; TREATMENT DURATION; TURKEY (REPUBLIC); WEIGHT GAIN;

ALPHA-MSH; ANTIPSYCHOTIC AGENTS; APPETITE REGULATION; BODY MASS INDEX; CASE-CONTROL STUDIES; HUMANS; HYPOTHALAMUS; LEPTIN; MALE; NERVE TISSUE PROTEINS; NEUROPEPTIDE Y; RISPERIDONE; TREATMENT OUTCOME; WEIGHT GAIN; YOUNG ADULT;

EID: 84883789882     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318297980e     Document Type: Article

References (51)

1. Purdon SE, Malla A, Labelle A, et al. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci. 2001;26:137-149
2. Keefe RS, Young CA, Rock SL, et al. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res. 2006;81:1-15
3. Centorrino F, Eakin M, Bahk WM, et al. Inpatient antipsychotic drug use in 1998, 1993, and 1989. Am J Psychiatr. 2002;159:1932-1935
4. Babiker IE. Noncompliance in schizophrenia. Psychiatr Dev. 1986;4:329-337
5. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 1995;21:419-429
6. Cookson JC. Side effects during long-Term treatment with depot antipsychotic medication. Clin Neuropharmacol. 1991;14(suppl 2): S24YS30; discussion S30YS32
7. Davies MA, Adena NA, Keks SV, et al. Risperidone versus haloperidol: I. Meta-Analysis of efficacy and safety. Clin Ther. 1998;20:58-71
8. Weiden PJ, Mackell J A, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004;66:51-57
9. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: Weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry. 2001;46:273-281
10. Nasrallah H. High prevalence of diabetes mellitus in schizophrenia, schizoaffective disorder, and bipolar disorder. Int J Neuropsychopharmacol. 2000;3(suppl 1):S116 (abstract P.01.096
11. Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychotic-induced weight gain: Insights into mechanisms of action. CNS Drugs. 2011;25:1035-1059
12. Lett TAP, Wallace TJM, Chowdhury NI, et al. Pharmacogenetics of antipsychotic-induced weight gain: Review and clinical implications. Mol Psychiatry. 2012;17:242-266
13. Basson BR, Kinon BJ, Taylor CC, et al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry. 2001;62:231-238
14. Briles JJ, Rosenberg DR, Brooks BA, et al. Review of the safety of second-generation antipsychotics: Are they really atypically safe for youth and adults? Prim Care Companion CNS Disord. 2012;14: PCC.11r01298
15. Chagnon YC. Susceptibility genes for the side effect of antipsychotics on body weight and obesity. Curr Drug Targets. 2006;12:1681-1695
16. Evans WE, Johnson JA. Pharmacogenomics: The inherited basis for inter-individual differences in drug response. Annu Rev Genomics Hum Genet. 2001;2:9-39
17. Correll CU, Anil K, Malhotra AK. Pharmacogenetics of antipsychotic induced weight gain. Psychopharmacology. 2004;174:477-489
18. Fernández E, Carrizo, E, Fernández V, et al. Polymorphisms of the LEP-And LEPR genes, metabolic profile after prolonged clozapine administration and response to the antidiabetic metformin. Schizophr Res. 2010;121:213-217
19. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ther. 2010;125: 169-179
20. Perez-Iglesias R, Mata I, Amado JA, et al. Effect of FTO, SH2B1, LEP, and LEPR polymorphisms on weight gain associated with antipsychotic treatment. J Clin Psychopharmacol. 2010;30(6):661-666
21. Srivastava V, Deshpande SN, Nimgaonkar VL, et al. Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from North India: Role of metabolic pathway genes. Pharmacogenomics. 2008;9(8):1055-1068
22. Brandl EJ, Frydrychowicz C, Tiwari AK, et al. Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain. Prog Neuropsychopharmacol Biol Psychiatry. 2012;38:134-141
23. Calarge CA, Ellingrod VL, Zimmerman B, et al. Leptin gene-2548G/A variants predict risperidone-Associated weight gain in children and adolescents. Psychiatr Genet. 2009;19(6):320-327
24. Cohen S, Glazewski R, Khan S, et al. Weight gain with risperidone among patients with mental retardation: Effect of calorie restriction. J Clin Psych. 2001;62:114-116
25. Russell JM, Mackell JA. Body weight gain associated with atypical antipsychotics: Epidemiology and therapeutic implications. CNS Drugs. 2001;15:537-551
26. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999;156:286-293
27. Farde L, Nyberg S, Oxenstierna G, et al. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-Treated schizophrenic patients. J Clin Psychopharmacol. 1995;15:19S-23S
28. Liliána ZF, János K, LászlóG, et al. Impact of haloperidol and risperidone on gene expression profile in the rat cortex. Neurochem Int. 2005;47:271-280
29. Konturek PC, Konturek JW, Czesnikiewicz G, et al. Neuro-hormonal control of food intake; basic mechanisms and clinical implications. J Physiol Clin Implications. 2005;56(suppl 6):5-25
30. Berthoud HR. Homeostatic and non-homeostatic pathways involved in the control of food intake and energy balance. Obesity. 2012;14:197-200
31. Heisler LK, Cowley MA, Tecott LH, et al. Activation of central melanocortin pathways by fenfluramine. Science. 2002;297(5581): 609-611
32. Jeanrenaud B, Rohner-Jeanrenaud F. Effects of neuropeptides and leptin on nutrient partitioning: Dysregulations in obesity. Annu Rev Med. 2001;52:339-351
33. Jin H, Meyer JM, Mudaliar S, et al. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res. 2008;100:70-85
34. Weigle DS, Bukowski TR, Foster DC, et al. Recombinant ob protein reduces feeding and body weight in the ob/ob mouse. J Clin Invest. 1995;96:2065-2070
35. Campfield L, Smith F, Gulsez Y, et al. Mouse OB protein: Evidence for a peripheral signal linking adiposity and central neural networks. Science. 1995;269:546-549
36. Currie PJ, Saxena N, Tu AY. 5-HT(2A/2C) receptor antagonists in the paraventricular nucleus attenuate the action of DOI on NPY stimulated eating. Neuroreport. 1999;10(14):3033-3036
37. Mas S, Gasso P, Bernardo M, et al. Functional analysis of gene expression in risperidone treated cells provide new insights in molecular mechanism and new candidate genes for pharmacogenetic studies. Eur Neuropsychopharmacol. 2013;23:329-337
38. Ak M, Sezlev D, Sutcigil L, et al. The investigation of leptin and hypothalamic neuropeptides role in first attack psychotic male patients: Olanzapine monotherapy. Psychoneuroendocrinology. 2013;33:341-347
39. Brooks JO, Chang HS, Krasnykh O. Metabolic risks in older adults receiving second-generation antipsychotic medication. Curr Psychiatry Rep. 2009;11(1):33-40
40. Cummings DE, SchwartzMW. Genetics and pathophysiology of human obesity. Annu Rev Med. 2003;54:453-471
41. Maayan LA, Vakhrusheva J. Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment. Hum Psychopharmacol. 2010;25(2): 133-138
42. Gruber SH, MathéAA. Effects of typical and atypical antipsychotics on neuropeptide Y in rat brain tissue and microdia-lysates from ventral striatum. J Neurosci Res. 2006;1:458-463
43. Charles A, Morgan III, Wang S, et al. Plasma neuropeptide-Y concentrations in humans exposed to military survival training. Biol Psychiatry. 2000;47:902-909
44. Wikberg JES, Muceniece R, Mandrika I, et al. New aspects on the melanocortins and their receptors. Pharmacol Res. 2000;42:393-420
45. Carrasco GA, Van de Kar LD. Neuroendocrine pharmacology of stress. Eur J Pharmacol. 2003;463:235-272
46. Van Praag HM. Can stress cause depression? Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:891-907
47. Cawley NX, Yanik T, Woronowicz A, et al. Obese carboxypeptidase E knockout mice exhibit multiple defects in peptide hormone processing contributing to low bone mineral density. Am J Physiol Endocrinol Metab. 2010;299(2):E189-E197
48. Rogge G, Jones D, Hubert GW, et al. CART peptides: Regulators of body weight, reward and other functions. Nat Rev Neurosci. 2008;10:747-758
49. Del Giudice EM, Santoro N, Cirillo G, et al. Mutational screening of the CART gene in obese children: Identifying a mutation (Leu34Phe) associated with reduced resting energy expenditure and co-segregating with obesity phenotype in a large family. Diabetes. 2001;50: 2157-2160
50. Yanik T, Dominguez G, Kuhar MJ, et al. The Leu34Phe ProCART mutation leads to cocaine-And amphetamine-regulated transcript (CART) deficiency: A possible cause for obesity in humans. Endocrinology. 2006;147(1):39-43
51. Harrold JA, Halford JC. The hypothalamus and obesity. Recent Patents CNS Drug Discov. 2006;3:305-314